Summary

Overview
Global Immuno-Oncology (IO)-Thematic Intelligence Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
Thematic intelligence in Immuno-Oncology involves systematically analyzing key themes, trends, and factors influencing cancer treatment through immune system modulation, utilizing diverse insights from various sources to gain a holistic view of the field.
Immuno-oncology agents have significantly improved cancer treatment, offering hope to patients with limited options. With over 700 novel agents in clinical development, including cell therapies and checkpoint modulators, continued investment in IO research is crucial for further advancements and improved clinical outcomes.
Market Dynamics: Drivers & Restraints
Rise in technological advancements
The rise in technological advancements in immunotherapies is one of the driving factors that help the market to grow during the forecast period. For instance, an area of innovation in India is the use of personalized medicine in immuno-oncology. This approach involves using genetic information about a patient’s tumour to select the most appropriate IO treatment for that individual. Research is being conducted to develop methods for identifying which patients are most likely to respond to immunotherapy drugs and to understand the mechanisms behind the clinical response.
Some of these path-breaking innovations have a significant artificial intelligence (AI) / machine learning (ML) component. AI is also being leveraged for assessing new and better combination therapies which involve using more than one type of existing treatment in conjunction with immunotherapy for better outcomes.
Furthermore, the global immuno-oncology (io)-thematic intelligence is also driven by various other factors like a rise in clinical trials and approval of IO therapies, a rise in demand for combination therapies and others helping the market to grow during the forecast period.
Overuse of combination therapies
The widespread use of combination therapies can make clinical trial design more complex, especially if no combination partner is currently approved or if clinical trials require acquisition or additional costs for the combination partner. The introduction of these combination therapies is expected to increase treatment costs, which may require new models for working with payers and demonstrating cost-effectiveness.
Segment Analysis
The global immuno-oncology (io)-thematic intelligence market is segmented based on type, indication, end-user and region.
The cytokines from the type segment accounted for approximately 38.1% of the immuno-oncology (io)-thematic intelligence market share
The cytokines from the type segment accounted for approximately 38.1%. Cytokine receptors are glycoproteins with an extracellular component, transmembrane domain, and cytoplasmic tail. After dimerization or oligomerization, they mediate numerous biological responses in cells. Soluble receptors can alter cytokine function or form complexes with a single cytokine to enhance ligand and receptor assembly. Depending on their function, several cytokines could be suitable for blockade by new small molecules.
For instance, in November 2023, Mural Oncology plc launched as an independent, publicly traded, clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers.
Geographical Analysis
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to the factors of clinical advancements, regulatory support, acquisitions, investment and funding and others that help the region to hold the highest market share during the forecast period.
For instance, in June 2023, Coherus BioSciences, Inc. and Surface Oncology, Inc. stated that the companies have entered into a definitive merger agreement providing that, at the closing, Coherus will acquire Surface Oncology, a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumour microenvironment.
The Surface acquisition adds two differentiated clinical stage assets to Coherus’ novel I-O pipeline: SRF388, a novel IL-27-targeted antibody currently being evaluated in Phase 2 clinical trials in lung cancer and liver cancer, and SFR114, a CCR8-targeted antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumours.
Covid 19 Impact Analysis
COVID-19 is causing significant disruptions in healthcare systems, particularly for cancer patients due to toxic treatments and frequent visits. Patients receiving immunotherapy (IO) drugs may require additional support to differentiate irAEs from COVID-19 symptoms. Oncology practices can minimize patient risk, expand care access, and facilitate clinical investigation continuity. Research into best practices and planning for COVID-19 spikes is crucial. Despite the strain on the cancer care delivery system, it is essential to improve the quality and resilience of this system.
Market Segmentation
By Type
• Cytokines
• Bispecific Antibodies
• Cancer Vaccines
• Cell Therapies
• Immune Checkpoint Inhibitors
• Oncolytic Viruses
By Indication
• Melanoma
• Kidney Cancer
• Liver Cancer
• Non-Small Cell Lung Cancer (NSCLC)
• Colorectal Cancer
• Others
By End User
• Pharmaceutical and Biotechnology companies
• Research Institutions
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Thermofisher Scientific, Merck & Co, Bristol Myers Squibb, F. Hoffmann-LA Roche Ltd, AstraZeneca, Novartis, Eli Lilly, Regeneron Pharmaceuticals, GSK, Fresenius Kabi among others.
Key Developments
 In November 2023, GE HealthCare’s Artificial Intelligence (AI) models predict patient response to immunotherapies with 70 to 80% accuracy, based on a pan-cancer cohort, according to findings to be presented at the Society for Immunotherapy of Cancer (SITC) in San Diego, U.S., by GE HealthCare, Vanderbilt University Medical Center (VUMC) and the University Medicine Essen (UME), Germany.
 In April 2023, AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics at AACR.
Why Purchase the Report?
• To visualize the global immuno-oncology (io)-thematic intelligence market segmentation based on type, indication, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analysing trends and co-development.
• Excel data sheet with numerous data points of immuno-oncology (IO)-thematic intelligence market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global immuno-oncology (IO)-thematic intelligence market report would provide approximately 64 tables, 61 figures and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Indication
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in technological advancements in immunotherapy
4.1.1.2. Rise in clinical trials and approval of IO therapies
4.1.2. Restraints
4.1.2.1. Overuse of combination therapies
4.1.2.2. XX
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Patent Analysis
5.6. PESTLE Analysis
5.7. SWOT Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Cytokines*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Bispecific Antibodies
7.4. Cancer Vaccines
7.5. Cell Therapies
7.6. Immune Checkpoint Inhibitors
7.7. Oncolytic Viruses
8. By Indication
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.1.2. Market Attractiveness Index, By Indication
8.2. Melanoma*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Kidney Cancer
8.4. Liver Cancer
8.5. Non-Small Cell Lung Cancer (NSCLC)
8.6. Colorectal Cancer
8.7. Others
9. By End User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Pharmaceutical and Biotechnology companies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Research Institutions
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Thermofisher Scientific*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Merck & Co
12.3. Bristol Myers Squibb
12.4. F. Hoffmann-LA Roche Ltd
12.5. AstraZeneca
12.6. Novartis
12.7. Eli Lilly
12.8. Regeneron Pharmaceuticals
12.9. GSK
12.10. Fresenius Kabi
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us